Personalized nutritional counseling appears essential in maintaining a low-protein diet.
No dominant treatment strategy was observed among 11 nephrology practices across the United States.
In a propensity score-matched analysis, children who discontinued renin-angiotensin-aldosterone system inhibition (RAASi) had significantly faster eGFR decline compared with those who continued RAASi.
In its first label update since sodium zirconium cyclosilicate was approved in 2018, FDA has a dosage regimen specifically to treat hyperkalemia in stable hemodialysis patients.
Case series and retrospective studies have shed some light on the safety and potential clinical and cardiovascular effects of MRAs in patients with end-stage kidney disease with and without heart failure.
Investigators newly identified pre-existing cardiac disorders in cotrimoxazole users as an AKI risk factor.
Preliminary research suggests sodium zirconium cyclosilicate may be an effective adjunct therapy to insulin and glucose in emergent hyperkalemia.
Study findings suggest the benefits of continuing ACEi or ARB therapy outweigh the risks in CKD patients with an eGFR less than 30 mL/min/1.73 m2.
Hyperkalemia, hypomagnesemia, and hyperparathyroidism commonly persist after kidney transplant surgery.
In a study, sodium zirconium cyclosilicatesimilarly maintained normokalemia in nondialysis CKD patients with an eGFR above and below a threshold of 30 mL/min/1.73 m2.